| |
Oestrogen-only users No. of GORD cases OR (95% CI) P
|
Tibolone users No. of GORD cases OR (95% CI) P
|
Combined HRT users No. of GORD cases OR (95% CI) P
|
Progestogen users No. of GORD cases OR (95% CI) P
|
|---|
|
PPI
|
|
Hormone
|
110
|
21
|
116
|
49
|
|
Non-hormone
|
467
|
467
|
467
|
467
|
|
OR (95% CI) p
|
1.34 (1.03–1.74) 0.027
|
0.76 (0.43–1.37) 0.367
|
1.15 (0.90–1.47) 0.250
|
1.50 (1.01–2.22) 0.044
|
|
NSAIDs <30d
|
|
Hormone
|
22
|
2
|
18
|
10
|
|
Non-hormone
|
81
|
81
|
81
|
81
|
|
OR (95% CI) p
|
1.57 (1.09–2.26) 0.016
|
0.83 (0.34–2.08) 0.700
|
1.57 (1.13–2.19) 0.008
|
1.15 (0.67–1.98) 0.606
|
|
NSAIDs ≥30d
|
|
Hormone
|
56
|
16
|
58
|
24
|
|
Non-hormone
|
200
|
200
|
200
|
200
|
|
OR (95% CI) p
|
2.02 (1.52–2.69) < 0.001
|
2.55 (1.41–4.63) 0.002
|
2.37 (1.82–3.07) < 0.001
|
1.61 (1.05–2.46) 0.029
|
|
Calcium <30d
|
|
Hormone
|
1
|
1
|
1
|
0
|
|
Non-hormone
|
11
|
11
|
11
|
11
|
|
OR (95% CI) p
|
0.97 (0.28–3.35) 0.959
|
2.78 (0.64–12.05) 0.172
|
1.21 (0.41–3.55) 0.732
|
3.60 (1.12–11.56) 0.031
|
|
Calcium ≥30d
|
|
Hormone
|
12
|
2
|
10
|
0
|
|
Non-hormone
|
29
|
29
|
29
|
29
|
|
OR (95% CI) p
|
1.98 (1.12–3.50) 0.019
|
2.9 (0.90–9.43) 0.075
|
1.21 (0.65–2.26) 0.555
|
1.85 (0.59–5.82) 0.293
|
|
Bisphosphonate <30d
|
|
Hormone
|
1
|
0
|
0
|
0
|
|
Non-hormone
|
3
|
3
|
3
|
3
|
|
OR (95% CI) p
|
3.05 (0.70–13.42) 0.139
|
- (−) 0.999
|
- (−) 0.999
|
1.50 (0.14–15.69) 0.737
|
|
Bisphosphonate ≥30d
|
|
Hormone
|
6
|
2
|
7
|
0
|
|
Non-hormone
|
18
|
18
|
18
|
18
|
|
OR (95% CI) p
|
1.96 (0.94–4.12) 0.074
|
1.70 (0.40–7.19) 0.474
|
2.01 (0.93–4.73) 0.075
|
1.38 (0.29–6.60) 0.685
|
- This table shows the number of prospective PPI users for hormone replacement use and non-use.
